Muhammad Izhar^1,*, Khadija Parwez², Saman Iftikhar³, Adeel Ahmad⁴, Shaikhan Bawazeer³, Saima Abdullah⁴

Journal on Artificial Intelligence, Vol.7, pp. 55-83, 2025, DOI:10.32604/jai.2025.062479 - 25 April 2025

Abstract The growing intersection of gynecological cancer diagnosis and cybersecurity vulnerabilities in healthcare necessitates integrated solutions that address both diagnostic accuracy and data protection. With increasing reliance on IoT-enabled medical devices, digital twins, and interconnected healthcare systems, the risk of cyber-physical attacks has escalated significantly. Traditional approaches to machine learning (ML)–based diagnosis often lack real-time threat adaptability and privacy preservation, while cybersecurity frameworks fall short in maintaining clinical relevance. This study introduces HealthSecureNet, a novel Cyber-Integrated Predictive Framework designed to detect gynecological cancer and mitigate cybersecurity threats in real time simultaneously. The proposed model employs a… More >

JINGDAN QUAN¹, ZIXIN WAN¹, WEI WU², XINYUAN CAO², JIAYUAN QIU², XIAOYE LIU², ZHIWEI ZHANG^1,*

Oncology Research, Vol.33, No.5, pp. 1069-1089, 2025, DOI:10.32604/or.2025.063005 - 18 April 2025

Abstract One of the most prevalent malignant tumors worldwide, stomach cancer still has a high incidence and fatality rate in China, and the number of young people developing early-onset gastric cancer is steadily increasing. The 5-year survival rate of stomach cancer is typically 30%–35%, the prognosis is bad, the patients’ quality of life is low, and the progression of advanced gastric cancer cannot be effectively managed despite the use of surgical surgery, chemotherapy, and other medicines. We urgently need molecular biomarkers with high specificity and sensitivity to increase the early gastric cancer detection rate, extend patient… More >

YU QIU^1,#, RUIHAN LIU^2,#, SHANSHAN HUANG¹, QIAOTING CAI¹, YI XIE¹, ZHITING HE¹, WEIGE TAN^2,*, XINHUA XIE^1,*

Oncology Research, Vol.33, No.5, pp. 1135-1147, 2025, DOI:10.32604/or.2025.062767 - 18 April 2025

Abstract Objectives: Deubiquitinase OTUB2 plays a critical role in the progression of various tumors. However, its specific role in triple-negative breast cancer (TNBC) remains unclear. This study aims to elucidate the biological function of OTUB2 in TNBC and uncover the underlying mechanisms. Methods: First, we found that the expression of OTUB2 was upregulated in TNBC by bioinformatics analysis, we then validated its expression in TNBC tissues and cells using immunohistochemistry (IHC) and qPCR and plotted the survival curves by Kaplan-Meier method. Gene set enrichment analysis (GSEA) suggested that OTUB2 may be involved in tumor proliferation and metastasis.… More > Graphic Abstract

XIAOBI HUANG¹, CHUNYUAN CHEN², YONGYANG CHEN¹, HONGLIAN ZHOU¹, YONGHUA CHEN¹, ZHONG HUANG¹, YULIU XIE¹, BAIYANG LIU¹, YUDONG GUO¹, ZHIXIONG YANG¹, GUANGHUA CHEN³, WENMEI SU^1,4

Oncology Research, Vol.33, No.5, pp. 1249-1250, 2025, DOI:10.32604/or.2024.061822 - 18 April 2025

Abstract This article has no abstract. More >

HYUNG SEOK KIM^*

Oncology Research, Vol.33, No.5, pp. 995-1000, 2025, DOI:10.32604/or.2025.060616 - 18 April 2025

Abstract The discovery of glycosylated RNA molecules, known as glycoRNAs, introduces a novel dimension to cellular biology. This commentary explores the transformative findings surrounding glycoRNAs, emphasizing their unique roles in cancer progression and the therapeutic opportunities they present. GlycoRNAs, through interactions with lectins and immune receptors, may contribute to tumor immune evasion. Moreover, the therapeutic potential of this emerging knowledge includes interventions targeting glycoRNA synthesis and modulation of associated signaling pathways. By highlighting these critical insights, this commentary aims to encourage the development of innovative strategies that could improve cancer prognosis and treatment. More >

TAYYABA SATTAR¹, IQRA NAZIR¹, MEHREEN JABBAR¹, JAVARIA MALIK¹, SABA AFZAL¹, SANA HANIF², SEYED ALI MOSADDAD³, AHMED HUSSAIN^4,*, HAMID TEBYANIYAN^2,*

Oncology Research, Vol.33, No.5, pp. 1019-1032, 2025, DOI:10.32604/or.2025.060601 - 18 April 2025

Abstract Background: Head and neck cancers (HNC) account for a significant global health burden, with increasing incidence rates and complex treatment requirements. Traditional diagnostic and therapeutic approaches, while effective, often result in substantial morbidity and limitations in personalized care. This review provides a comprehensive overview of the latest innovations in diagnostics and therapeutic strategies for HNC from 2015 to 2024. Methods: A review of literature focused on pe-reviewed journals, clinical trial databases, and oncology conference proceedings. Key areas include molecular diagnostics, imaging technologies, minimally invasive surgeries, and innovative therapeutic strategies. Results: Technologies like liquid biopsy next-generation sequencing… More >

HYEONG SIM CHOI¹, JEONG-KUI KU¹, SEONG-GYU KO², PIL-YOUNG YUN^1,3,*

Oncology Research, Vol.33, No.5, pp. 1217-1227, 2025, DOI:10.32604/or.2025.059791 - 18 April 2025

Abstract Background: Oral cancer remains a significant global health challenge, as it has high morbidity and mortality rates. Current treatments show limited efficacy and have severe side effects, prompting searches for new therapeutic agents. SH003, a traditional herbal formulation comprising Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, has demonstrated potential anticancer properties in previous studies. However, its specific efficacy against oral cancer and the role of its key components, particularly Cucurbitacin D, remain underexplored. Methods: The cytotoxic effects of SH003 and its major components—i.e., Cucurbitacin D, Decursin, Formononetin, and Nodakenin—were evaluated using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT), Trypan Blue exclusion, and… More >

MOEKA NAKASHIMA, NAOKO SUGA, AKARI FUKUMOTO, SAYURI YOSHIKAWA, SATORU MATSUDA^*

Oncology Research, Vol.33, No.5, pp. 1007-1017, 2025, DOI:10.32604/or.2025.059657 - 18 April 2025

Abstract Malignant tumors are heterogeneous diseases characterized by uncontrolled cell proliferation, invasion, metastasis, and/or recurrence of their malignancies. In particular, cancer stem cells (CSCs) within these tumors might be responsible for the property of invasiveness and/or therapies-resistance. CSCs are a self-renewing, awfully tumorigenic subpopulation of cancer cells, which are notorious for strong chemoresistance and are frequently responsible the aggravated invasion, metastasis, and/or recurrence. Developing targeting therapies against CSCs, therefore, may be deliberated a more encouraging mission for the greater cancer therapy. Innovation for a more potent anti-CSC treatment has been required as soon as possible.… More > Graphic Abstract

JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

CHENXIAO QIAO¹, YIPENG XU², YEDIE HE², ZHIJIAN CAI^1,*, HUA WANG^2,*

Oncology Research, Vol.33, No.5, pp. 1161-1172, 2025, DOI:10.32604/or.2024.055746 - 18 April 2025

Abstract Objective: To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab. Methods: Anti-tumor efficacy of intratumoral injection of H101 or/and intraperitoneal injection of Camrelizumab were evaluated in an immune system humanized NOD Prkdc^scid Il2rg^-/- mice subcutaneous (S.C.) tumor model, established with human glioblastoma of unknown origin cell line U87-MG, and human bladder cancer cell line T24 and YTS-1. The mechanism by which H101 induced anti-tumor immunity were also investigated. Results: Combining H101 with Camrelizumab demonstrated more potent anti-tumor effects than monotherapy in… More >